Independent equity research
Company analysis, SEC filing changes and public follow-ups. Read the thesis, inspect the assumptions, and see what happened next.
Free research to read now. Premium research is coming.
New to LF0?
Understand a thesis. Audit a call. Compare a filing.
01 / Read a stock thesis
FormFactor (FORM) is rated Hold as AI and HBM demand are driving strong growth, but the stock already discounts much of the upside. Rich valuation and customer concentration keep the…
Read the research02 / Check the follow-up
Revisiting our Buy call on GFI: entry $35.69, latest $34.77, -2.6%.
Read the research03 / See what changed
Naploy (NPLY) 2026 10-K analysis comparing the 30 October 2026 filing with its prior-year 10-K, highlighting the MD&A section's biggest changes.
Read the researchFrom the research desk
Willdan Group (WLDN) is rated Hold as growth improves but the stock already reflects much of the progress. Revenue and EBITDA have strengthened, yet execution risk remains if operating margin…
Read the researchHalozyme Therapeutics (HALO) is rated HOLD as strong ENHANZE growth and margins are balanced by a rich valuation and meaningful debt. The stock already prices in much of the platform's…
Read the researchmonday.com (MNDY) is rated Hold as revenue growth remains strong, but operating leverage is still too thin to support a higher multiple. The stock looks reasonable on EV/revenue, yet weak…
Read the researchNaploy (NPLY) 2026 10-K analysis comparing the 30 October 2026 filing with its prior-year 10-K, highlighting the MD&A section's biggest changes.
Read the researchRafael Holdings (RFL)'s MD&A section changed the most among 6 companies that filed 10-Ks on 29 October 2026, each compared against its prior-year filing.
Read the researchZedge (ZDGE)'s Business section changed the most among 5 companies that filed 10-Ks on 28 October 2026, each compared against its prior-year filing.
Read the researchRevisiting our Buy call on GFI: entry $35.69, latest $34.77, -2.6%.
Read the researchRevisiting our Sell call on NVTS: entry $12.34, latest $7.93, -35.7%.
Read the researchRevisiting our Sell call on FTNT: entry $156.25, latest $136.08, -12.9%.
Read the researchLF0 Research Desk
A rating is a thesis to examine. The original analysis and later scorecard reviews let you see both the reasoning and the outcome.
Stay connected
The current research is free to browse. The waitlist is for news about deeper premium analysis when it launches.
This form joins the LF0 premium waitlist. Substack is a separate subscription. You can read the current research without joining either.
Follow your interests
Explore more of the company analyses featured on LF0.